Non-Muscle Invasive Bladder Cancer (NMIBC) Market

Jul 28, 2020

30 likes | 53 Views

The total diagnosed prevalent population of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM was 533,263 in 2017. The diagnosed prevalent population of NMIBC in Japan in 2017 was 74,691. The EU5 countries ( i.e the Uk, Spain, France, Germany, Italy) occupied approximately 45.90% of the patient pool amongst seven major markets. The market size of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM was found to be USD 1,454 Million in 2017, which is expected to increase during the study period 2017-2030. Imminent launches, upsurge in research and development, enriched understanding, and increased incidence are some of the key factors expected to drive the NMIBC market forward in the coming years. The key pharma players in the Non-Muscle Invasive Bladder Cancer (NMIBC) Market includes Sesen Bio, Bristol-Myers Squibb,Janssen Pharmaceutical, Ferring Pharmaceuticals, FKD Therapies, AstraZeneca, Celgene,Hamlet Pharma, Roche, UroGen Pharma, ImmunityBio, Altor BioScience, TesoRx Pharma, Pfizer, Incyte Corporation, Theralase,Spectrum Pharmaceuticals, CG Oncology, EMD Serono and many others. For more details visit: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

DelveInsight

Download Presentation

Non-Muscle Invasive Bladder Cancer (NMIBC) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D